Cosmax Nbt, Inc. (KOSDAQ:222040)
8,310.00
+250.00 (3.10%)
At close: Aug 24, 2026
Cosmax Nbt Revenue
Cosmax Nbt had revenue of 102.26B KRW in the quarter ending June 30, 2026, with 35.18% growth. This brings the company's revenue in the last twelve months to 335.18B, up 6.78% year-over-year. In the year 2025, Cosmax Nbt had annual revenue of 287.48B, down -9.59%.
Revenue (ttm)
335.18B
Revenue Growth
+6.78%
P/S Ratio
0.49
Revenue / Employee
653.37M
Employees
513
Market Cap
165.67B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 287.48B | -30.51B | -9.59% |
| Dec 31, 2024 | 317.99B | -15.65B | -4.69% |
| Dec 31, 2023 | 333.63B | 5.42B | 1.65% |
| Dec 31, 2022 | 328.21B | 38.86B | 13.43% |
| Dec 31, 2021 | 289.35B | 22.56B | 8.45% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| NOVAREX | 404.26B |
| Ahn-Gook Pharmaceutical | 330.05B |
| Kyung Dong Pharmaceutical | 198.27B |
| GC WellBeing | 179.05B |
| DAE HWA Pharmaceutical | 148.75B |
| HYUNDAI BIOLAND | 135.04B |
| WITHUS PHARMACEUTICAL Co.,LTD. | 108.89B |
| High Tech Pharm | 69.05B |